Clinical crusade: zosurabalpin's charge against antibiotic resistance

Wancai Que; Zixin Deng; Jiangtao Gao

doi:10.1016/j.molmed.2024.02.012

Clinical crusade: zosurabalpin's charge against antibiotic resistance

Trends Mol Med. 2024 May;30(5):420-422. doi: 10.1016/j.molmed.2024.02.012. Epub 2024 Mar 7.

Authors

Wancai Que¹, Zixin Deng², Jiangtao Gao³

Affiliations

¹ Key BioAI Synthetica Laboratory for Natural Product Drug Discovery, College of Bee and Biomedical Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China.
² State Key Laboratory of Microbial Metabolism, Joint International Laboratory of Metabolic and Developmental Sciences, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, 800 Dongchuan Road, Shanghai 200240, China.
³ Key BioAI Synthetica Laboratory for Natural Product Drug Discovery, College of Bee and Biomedical Sciences, Fujian Agriculture and Forestry University, Fuzhou 350002, China. Electronic address: jgaotao@gmail.com.

PMID: 38453528
DOI: 10.1016/j.molmed.2024.02.012

Abstract

In a recent report, Zampaloni et al. describe a novel tethered macrocyclic peptide (MCP) antibiotic, zosurabalpin, that disrupts the essential function of the LptB₂FGC complex in Gram-negative bacteria and demonstrates efficacy against carbapenem-resistant Acinetobacter baumannii (CRAB). Its preclinical success suggests a substantial shift in treating antibiotic resistance, pending clinical trials to validate its effectiveness, pharmacokinetics, and resistance management.

MeSH terms

Acinetobacter baumannii / drug effects
Animals
Anti-Bacterial Agents* / pharmacology
Anti-Bacterial Agents* / therapeutic use
Drug Resistance, Bacterial / drug effects
Humans
Peptides, Cyclic / chemistry
Peptides, Cyclic / pharmacology
Peptides, Cyclic / therapeutic use

Substances

Anti-Bacterial Agents
Peptides, Cyclic